OncoMatch/Clinical Trials/NCT04018872
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Is NCT04018872 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Itraconazole for esophagus adenocarcinoma.
Treatment: Itraconazole — Esophageal cancer, which has a low 5-year overall survival rate for all stages (\<20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are activated in a significant proportion of esophageal cancers. Itraconazole, a widely used anti-fungal medication, has been shown to inhibit various pathways involved in esophageal cancer tumorigenesis including Hh and AKT. In this phase II clinical trial, the investigators aim to evaluate the effect of itraconazole as a neoadjuvant therapy following standard of care chemoradiation in the treatment of locoregional esophageal and gastroesophageal junction carcinomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Esophageal Carcinoma
Disease stage
Required: Stage LOCALIZED, LOCOREGIONAL
localized (locoregional) esophageal cancer; localized (locoregional) gastroesophageal junction cancer
Lab requirements
Liver function
LFT's >3xULN excluded
Cardiac function
QTc >450ms excluded; history of symptomatic congestive heart failure excluded
QTc>450ms; history of symptomatic congestive heart failure; LFT's>3xULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dallas VA Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify